Rating Change
Truist Securities reiterated its Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK) on August 10, 2026.
reiterateNASDAQ:CYTK
Truist Securities Reiterates Buy Rating on Cytokinetics, Incorporated (CYTK)
Truist Securities reiterated its Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK) on August 10, 2026.
At publication ·
What changed
Cytokinetics, Incorporated (NASDAQ:CYTK) · reiterate
- Firm
- Truist Securities
- Rating
- Buy to Buy
- Price at event
- $77.49
- Market capitalization
- $7.2B
At a glance
Key takeaways
- Truist Securities reiterated a Buy rating on Cytokinetics (CYTK) on August 10, 2026, with the stock trading at $77.49 and a market capitalization of $7.2 billion.
Market Context
Cytokinetics, Incorporated operates in the Healthcare sector. The stock currently trades at $77.49 with a market capitalization of $7.2B. The stock has gained 117.8% over the past 52 weeks.
Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cytokinetics, Incorporated.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Cytokinetics, Incorporated
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | Truist Securities | Buy | N/A |
| Aug 07, 2026 | RBC Capital | Outperform | N/A |
| Aug 07, 2026 | Citizens | Market Outperform | N/A |
| Aug 07, 2026 | Needham | Buy | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CYTK Stock Page
Frequently Asked Questions
What does the Buy rating mean for CYTK?
A rating of Buy from Truist Securities reflects the analyst's outlook on Cytokinetics, Incorporated (NASDAQ:CYTK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CYTK forecast page.